Protection of humanized mice from repeated intravaginal HIV challenge by passive immunization: A model for studying the efficacy of neutralizing antibodies in vivo

Journal of Infectious Diseases

Volumn 214, Issue 4, 2016, Pages 612-616

  Deruaz, Maud ^a   Moldt, Brian ^c   Le, Khoa M ^c   Power, Karen A ^b   Vrbanac, Vladimir D ^a,b   Tanno, Serah ^a,b   Ghebremichael, Musie S ^b   Allen, Todd M ^b   Tager, Andrew M ^a,b   Burton, Dennis R ^b,c   Luster, Andrew D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

HIV transmission; Humanized mice; Mucosal infection; Neutralizing antibodies

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY B12; PGT 126 VACCINE; UNCLASSIFIED DRUG; VIRUS RNA; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4 LYMPHOCYTE PERCENTAGE; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG POTENCY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFECTION RISK; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VIRUS NEUTRALIZATION; ANIMAL; DISEASE MODEL; DOSE RESPONSE; HIV INFECTIONS; PROCEDURES; SCID MOUSE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, NEUTRALIZING; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; IMMUNIZATION, PASSIVE; MICE; MICE, SCID; TREATMENT OUTCOME;

EID: 84988916161     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw203     Document Type: Article

References (15)

1. Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC. Antibodies in HIV-1 vaccine development and therapy. Science 2013; 341:1199-204.
2. Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012; 492:118-22.
3. Caskey M, Klein F, Lorenzi JC, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015; 522:487-91.
4. Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 2014; 158:1243-53.
5. Denton PW, Estes JD, Sun Z, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008; 5:e16.
6. Gruell H, Bournazos S, Ravetch JV, Ploss A, Nussenzweig MC, Pietzsch J. Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. J Virol 2013; 87:8535-44.
7. Veselinovic M, Neff CP, Mulder LR, Akkina R. Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 2012; 432: 505-10.
8. Hur EM, Patel SN, Shimizu S, et al. Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood 2012; 120: 4571-82.
9. Balazs AB, Ouyang Y, Hong CM, et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med 2014; 20:296-300.
10. Brainard DM, Seung E, Frahm N, et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virusinfected humanized BLT mice. J Virol 2009; 83:7305-21.
11. Burton DR, Pyati J, Koduri R, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266:1024-7.
12. Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011; 477:466-70.
13. Nath BM, Schumann KE, Boyer JD. The chimpanzee and other non-human-primate models in HIV-1 vaccine research. Trends Microbiol 2000; 8:426-31.
14. Moldt B, Rakasz EG, Schultz N, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 2012; 109:18921-5.
15. Hessell AJ, Poignard P, Hunter M, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009; 15:951-4.